-
3
-
-
77349083001
-
Nationwide Cancer Incidence in Korea, 2003-2005
-
Won Y, Sung J, Jung K, et al. Nationwide Cancer Incidence in Korea, 2003-2005. Cancer Res Treat 2009; 41: 122-31.
-
(2009)
Cancer Res Treat
, vol.41
, pp. 122-131
-
-
Won, Y.1
Sung, J.2
Jung, K.3
-
4
-
-
0025060806
-
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma
-
Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352-8.
-
(1990)
N Engl J Med
, vol.322
, pp. 352-358
-
-
Moertel, C.G.1
Fleming, T.R.2
MacDonald, J.S.3
-
5
-
-
0031022988
-
Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer
-
O'Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15: 246-50.
-
(1997)
J Clin Oncol
, vol.15
, pp. 246-250
-
-
O'Connell, M.J.1
Mailliard, J.A.2
Kahn, M.J.3
-
6
-
-
2542615200
-
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
-
Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-51.
-
(2004)
N Engl J Med
, vol.350
, pp. 2343-2351
-
-
Andre, T.1
Boni, C.2
Mounedji-Boudiaf, L.3
-
7
-
-
67650315187
-
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial
-
Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-16.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3109-3116
-
-
Andre, T.1
Boni, C.2
Navarro, M.3
-
8
-
-
79953217628
-
5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer
-
Jover R, Nguyen TP, Perez-Carbonell L, et al. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology 2011; 140: 1174-81.
-
(2011)
Gastroenterology
, vol.140
, pp. 1174-1181
-
-
Jover, R.1
Nguyen, T.P.2
Perez-Carbonell, L.3
-
9
-
-
46349086833
-
Association between chromosomal instability and prognosis in colorectal cancer: A meta-analysis
-
Walther A, Houlston R, Tomlinson I,. Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut 2008; 57: 941-50.
-
(2008)
Gut
, vol.57
, pp. 941-950
-
-
Walther, A.1
Houlston, R.2
Tomlinson, I.3
-
10
-
-
37149041833
-
Molecular classification and correlates in colorectal cancer
-
Ogino S, Goel A,. Molecular classification and correlates in colorectal cancer. J Mol Diagn 2008; 10: 13-27.
-
(2008)
J Mol Diagn
, vol.10
, pp. 13-27
-
-
Ogino, S.1
Goel, A.2
-
11
-
-
72449176846
-
Molecular origins of cancer: Molecular basis of colorectal cancer
-
Markowitz SD, Bertagnolli MM,. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 2009; 361: 2449-60.
-
(2009)
N Engl J Med
, vol.361
, pp. 2449-2460
-
-
Markowitz, S.D.1
Bertagnolli, M.M.2
-
12
-
-
77951627056
-
The chromosomal instability pathway in colon cancer
-
Pino MS, Chung DC,. The chromosomal instability pathway in colon cancer. Gastroenterology 2010; 138: 2059-72.
-
(2010)
Gastroenterology
, vol.138
, pp. 2059-2072
-
-
Pino, M.S.1
Chung, D.C.2
-
13
-
-
77449130761
-
Microsatellite instability in colorectal cancer
-
e3
-
Boland CR, Goel A,. Microsatellite instability in colorectal cancer. Gastroenterology 2010; 138: 2073-87 e3.
-
(2010)
Gastroenterology
, vol.138
, pp. 2073-2087
-
-
Boland, C.R.1
Goel, A.2
-
14
-
-
10744228074
-
Use of 5-fluorouracil and survival in patients with microsatellite- unstable colorectal cancer
-
Carethers JM, Smith EJ, Behling CA, et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004; 126: 394-401.
-
(2004)
Gastroenterology
, vol.126
, pp. 394-401
-
-
Carethers, J.M.1
Smith, E.J.2
Behling, C.A.3
-
15
-
-
0038002279
-
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer
-
Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247-57.
-
(2003)
N Engl J Med
, vol.349
, pp. 247-257
-
-
Ribic, C.M.1
Sargent, D.J.2
Moore, M.J.3
-
16
-
-
33745541234
-
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer
-
Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006; 38: 787-93.
-
(2006)
Nat Genet
, vol.38
, pp. 787-793
-
-
Weisenberger, D.J.1
Siegmund, K.D.2
Campan, M.3
-
17
-
-
73449118889
-
Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers
-
Kim JH, Shin SH, Kwon HJ, et al. Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. Virchows Arch 2009; 455: 485-94.
-
(2009)
Virchows Arch
, vol.455
, pp. 485-494
-
-
Kim, J.H.1
Shin, S.H.2
Kwon, H.J.3
-
18
-
-
56649084987
-
Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample
-
Nosho K, Irahara N, Shima K, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One 2008; 3: e3698.
-
(2008)
PLoS One
, vol.3
-
-
Nosho, K.1
Irahara, N.2
Shima, K.3
-
19
-
-
77949759545
-
The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status
-
Dahlin AM, Palmqvist R, Henriksson ML, et al. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin Cancer Res 2010; 16: 1845-55.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 1845-1855
-
-
Dahlin, A.M.1
Palmqvist, R.2
Henriksson, M.L.3
-
20
-
-
79955397102
-
DNA methylation predicts recurrence from resected stage III proximal colon cancer
-
Ahn JB, Chung WB, Maeda O, et al. DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer 2011; 117: 1847-54.
-
(2011)
Cancer
, vol.117
, pp. 1847-1854
-
-
Ahn, J.B.1
Chung, W.B.2
Maeda, O.3
-
21
-
-
58249089525
-
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer
-
Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009; 58: 90-6.
-
(2009)
Gut
, vol.58
, pp. 90-96
-
-
Ogino, S.1
Nosho, K.2
Kirkner, G.J.3
-
22
-
-
0041524111
-
CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer
-
Van Rijnsoever M, Elsaleh H, Joseph D, et al. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res 2003; 9: 2898-903.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 2898-2903
-
-
Van Rijnsoever, M.1
Elsaleh, H.2
Joseph, D.3
-
23
-
-
79961137937
-
The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy
-
Min BH, Bae JM, Lee EJ, et al. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy. BMC Cancer 2011; 11: 344.
-
(2011)
BMC Cancer
, vol.11
, pp. 344
-
-
Min, B.H.1
Bae, J.M.2
Lee, E.J.3
-
24
-
-
77951967408
-
Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin
-
Zaanan A, Cuilliere-Dartigues P, Guilloux A, et al. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol 2010; 21: 772-80.
-
(2010)
Ann Oncol
, vol.21
, pp. 772-780
-
-
Zaanan, A.1
Cuilliere-Dartigues, P.2
Guilloux, A.3
-
25
-
-
78149327190
-
Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy
-
Kim ST, Lee J, Park SH, et al. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol 2010; 66: 659-67.
-
(2010)
Cancer Chemother Pharmacol
, vol.66
, pp. 659-667
-
-
Kim, S.T.1
Lee, J.2
Park, S.H.3
-
26
-
-
33744550591
-
Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis
-
Ogino S, Kawasaki T, Brahmandam M, et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 2006; 8: 209-17.
-
(2006)
J Mol Diagn
, vol.8
, pp. 209-217
-
-
Ogino, S.1
Kawasaki, T.2
Brahmandam, M.3
-
27
-
-
20244383592
-
Evidence for BRAF mutation and variable levels of microsatellite instability in a syndrome of familial colorectal cancer
-
Young J, Barker MA, Simms LA, et al. Evidence for BRAF mutation and variable levels of microsatellite instability in a syndrome of familial colorectal cancer. Clin Gastroenterol Hepatol 2005; 3: 254-63.
-
(2005)
Clin Gastroenterol Hepatol
, vol.3
, pp. 254-263
-
-
Young, J.1
Barker, M.A.2
Simms, L.A.3
-
28
-
-
34247570795
-
Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample
-
Ogino S, Kawasaki T, Kirkner GJ, et al. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn 2007; 9: 305-14.
-
(2007)
J Mol Diagn
, vol.9
, pp. 305-314
-
-
Ogino, S.1
Kawasaki, T.2
Kirkner, G.J.3
-
29
-
-
0035830503
-
Neurogenin promotes neurogenesis and inhibits glial differentiation by independent mechanisms
-
Sun Y, Nadal-Vicens M, Misono S, et al. Neurogenin promotes neurogenesis and inhibits glial differentiation by independent mechanisms. Cell 2001; 104: 365-76.
-
(2001)
Cell
, vol.104
, pp. 365-376
-
-
Sun, Y.1
Nadal-Vicens, M.2
Misono, S.3
-
30
-
-
33747587608
-
Regulation of the INK4b-ARF-INK4a tumour suppressor locus: All for one or one for all. Nature reviews
-
Gil J, Peters G,. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nature reviews. Mol Cell Biol 2006; 7: 667-77.
-
(2006)
Mol Cell Biol
, vol.7
, pp. 667-677
-
-
Gil, J.1
Peters, G.2
-
31
-
-
54249165951
-
Hypermethylator phenotype in sporadic colon cancer: Study on a population-based series of 582 cases
-
Barault L, Charon-Barra C, Jooste V, et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res 2008; 68: 8541-6.
-
(2008)
Cancer Res
, vol.68
, pp. 8541-8546
-
-
Barault, L.1
Charon-Barra, C.2
Jooste, V.3
-
32
-
-
78650733422
-
Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review
-
Shima K, Nosho K, Baba Y, et al. Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: cohort study and literature review. Int J Cancer 2011; 128: 1080-94.
-
(2011)
Int J Cancer
, vol.128
, pp. 1080-1094
-
-
Shima, K.1
Nosho, K.2
Baba, Y.3
-
33
-
-
77954954112
-
Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas
-
Kim JC, Choi JS, Roh SA, et al. Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas. Ann Surg Oncol 2010; 17: 1767-76.
-
(2010)
Ann Surg Oncol
, vol.17
, pp. 1767-1776
-
-
Kim, J.C.1
Choi, J.S.2
Roh, S.A.3
-
34
-
-
22244472992
-
Poor Survival Associated with the BRAF V600E Mutation in Microsatellite-Stable Colon Cancers
-
Samowitz WS, Sweeney C, Herrick J, et al. Poor Survival Associated with the BRAF V600E Mutation in Microsatellite-Stable Colon Cancers. Cancer Res 2005; 65: 6063-9.
-
(2005)
Cancer Res
, vol.65
, pp. 6063-6069
-
-
Samowitz, W.S.1
Sweeney, C.2
Herrick, J.3
-
35
-
-
79958806016
-
Four molecular subtypes of colorectal cancer and their precursor lesions
-
Kang GH,. Four molecular subtypes of colorectal cancer and their precursor lesions. Arch Pathol Lab Med 2011; 135: 698-703.
-
(2011)
Arch Pathol Lab Med
, vol.135
, pp. 698-703
-
-
Kang, G.H.1
-
36
-
-
77957197346
-
Microsatellite instability as a marker of prognosis and response to therapy: A meta-analysis of colorectal cancer survival data
-
Guastadisegni C, Colafranceschi M, Ottini L, et al. Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. Eur J Cancer 2010; 46: 2788-98.
-
(2010)
Eur J Cancer
, vol.46
, pp. 2788-2798
-
-
Guastadisegni, C.1
Colafranceschi, M.2
Ottini, L.3
-
37
-
-
82555173112
-
Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy
-
Zaanan A, Fléjou J-Fo, Emile J-Fo, et al. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy. Clin Cancer Res 2011; 17: 7470-8.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 7470-7478
-
-
Zaanan, A.1
Fléjou, J.-F.2
Emile, J.-F.3
-
38
-
-
64649096900
-
Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and leukemia group B protocol 89803
-
Bertagnolli MM, Niedzwiecki D, Compton CC, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: cancer and leukemia group B protocol 89803. J Clin Oncol 2009; 27: 1814-21.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1814-1821
-
-
Bertagnolli, M.M.1
Niedzwiecki, D.2
Compton, C.C.3
-
39
-
-
38149135181
-
Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation
-
Lee S, Cho NY, Choi M, et al. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. Pathol Int 2008; 58: 104-13.
-
(2008)
Pathol Int
, vol.58
, pp. 104-113
-
-
Lee, S.1
Cho, N.Y.2
Choi, M.3
-
40
-
-
54449092791
-
CpG island methylator phenotype in colorectal cancers: Comparison of the new and classic CpG island methylator phenotype marker panels
-
Lee S, Cho NY, Yoo EJ, et al. CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels. Arch Pathol Lab Med 2008; 132: 1657-65.
-
(2008)
Arch Pathol Lab Med
, vol.132
, pp. 1657-1665
-
-
Lee, S.1
Cho, N.Y.2
Yoo, E.J.3
-
41
-
-
33644834827
-
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials
-
Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005; 23: 8664-70.
-
(2005)
J Clin Oncol
, vol.23
, pp. 8664-8670
-
-
Sargent, D.J.1
Wieand, H.S.2
Haller, D.G.3
|